Partner Content Partner Content Focus day announced for SMi’s 11th annual RNA Therapeutics c... SMi Reports: RNA Therapeutics conference and focus day to return on February 2020, in London
Events Partner Content 2nd RNA Targeted Drug Discovery Summit At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the
News BMS looks to RNA splicing to boost immunotherapies Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to
News Dicerna agrees another gene-silencing deal, this time with L... Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.